Skip to main content
. Author manuscript; available in PMC: 2020 Jul 12.
Published in final edited form as: ACS Infect Dis. 2019 May 14;5(7):1139–1149. doi: 10.1021/acsinfecdis.9b00010

Figure 6. BNBC activated type I and III interferon dominated inflammatory cytokine response in PBMC-derived dendritic cells, and promoted dendritic cell maturation.

Figure 6.

(A) Human PBMC-derived dendritic cells were treated with 10 μg/ml LPS or 100 μM of BNBC for 6 h. Cytokine mRNAs were detected by qRT-PCR and expressed as fold of induction relative to mock treated control (mean ± standard deviation, n=3). (B and C) Human PBMC-derived dendritic cells were treated with 10 μg/ml LPS or 50 μM of BNBC for 48 h. CD80 expression was gated from CD11c+ cells (B). Fluorescent intensity of CD80 from 4 independent experiments using PBMCs from 2 donors were expressed as mean ± standard deviation (MFI) (C). * indicates p< 0.05 compared to mock treated control.